



November 22, 1994

SYMPHONY
 PHARMACEUTICALS, INC.
 74 GREAT VALLEY PARKWAY
 MALVERN, PA 19355
 TEL: 215 640-4870
 FAX: 215 640-5750

Mr. John R. McGrath
 Acting Chief
 Medical Inspection Section
 Division of Radiation Safety and Safeguards
 Nuclear Regulatory Commission
 Region I
 475 Allendale Road
 King of Prussia, PA 19406-1415

Re: Reply to a Notice of Violation
 Routine Inspection No. 030-33344 / 94-01
 License No. 37-30091-01

Dear Mr. McGrath:

After discussions with Ms. Mary Cahill on September 26, 1994, we have instituted a number of changes to address those areas in which we were not fully compliant with our NRC license. Specifically, the following changes have been made.

Items A.1. and A.2.

We have redesigned our survey procedures so that surveys are now performed and records thereof kept in accordance with item 10 (I) of our February 21, 1994, letter and as required by Condition 17 of our license. We have also performed the required surveys for the month of October and have completed a survey under the direction of the Radiation Safety Officer for the 4th quarter of 1994.

Item B.

We have performed a survey to determine that the quantity of radioactivity released into the sewer system in any month during 1994 did not exceed the concentration specified in Table 3, Appendix B to 10 CFR 20.1001 - 20.2401. Also we have revised our procedures to include these surveys as part of our routine survey program.

NOV 25 1994

9501180130 950106
 PDR ADOCK 03033344
 C PDR

Mr. John R. McGrath
November 22, 1994
Page 2

Item C.


We have, for each individual who was monitored pursuant to 10 CFR 20.1502, determined the occupational radiation dose received during 1994. In addition, we have undertaken the retrieval of records of lifetime cumulative doses for each of these individuals from previous employers. Our procedures were revised to include occupational radiation dose evaluations for individuals who require monitoring pursuant to 10 CFR 20.1502.

Item D.

We have posted the notice required pursuant to 10 CFR 19 (a) and (b).

Most of the corrective actions were taken promptly after the inspection by Ms. Cahill. Some further actions were taken after we received the report dated November 1, 1994, and full compliance was achieved prior to the date of this letter.

Sincerely,



Duncan P. Taylor, Ph.D.
Director, Pharmacology

cc: U.S. Nuclear Regulatory Commission, Washington, D.C.